HI
PTGX icon

Harbour Investments’s Protagonist Therapeutics PTGX Stock Holding History

Harbour Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.41K Buy
36
+17
+89% +$1.78K ﹤0.01% 3739
2026
Q1 		$2.04K Buy
19
+17
+850% +$1.5K ﹤0.01% 3902
2025
Q4 		$175 Buy
+2
New +$164 ﹤0.01% 3691
2021
Q4 		– Sell
-126
Closed -$2K – 3451
2021
Q3 		$2K Buy
126
+51
+68% +$2.17K ﹤0.01% 3351
2021
Q2 		$3K Buy
75
+2
+3% +$66 ﹤0.01% 3267
2021
Q1 		$2K Buy
+73
New +$1.85K ﹤0.01% 3255

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harbour Investments's PTGX Position: Q2 2026 in Review

Harbour Investments increased its Protagonist Therapeutics (PTGX) stake by 89% in Q2 2026, buying an estimated $1.78K and bringing the position to 36 shares worth $4.41K. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

Harbour Investments first reported a position in PTGX in Q1 2021 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Harbour Investments held 36 shares of Protagonist Therapeutics worth $4.41K as of Q2 2026.
  • Harbour Investments bought 17 Protagonist Therapeutics shares in Q2 2026, an estimated $1.78K.
  • Protagonist Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3739 holding.
  • Harbour Investments first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.